[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-340898-105":59,"doc-detail-340898-en":131},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":124,"head_meta":126,"extra_data":128,"updated_unix":130},105,"en","protac-mediated-nr4a1-degradation-as-a-novel-strategy-for-cancer-immunotherapy-article","PROTAC-mediated NR4A1 degradation as a novel strategy for cancer immunotherapy - Article","","An effective cancer therapy must eradicate tumor cells while reshaping the tumor microenvironment (TME). This study identifies NR4A1 as a molecule that maintains an immune-suppressive TME and establishes it as a target for cancer immunotherapy. A first-in-class PROTAC (NR-V04) is developed, producing rapid NR4A1 degradation in vitro, sustained degradation in tumors, strong antitumor activity, and an excellent safety profile. Mechanistically, NR-V04 promotes tumor-infiltrating B cells and effector memory CD8+ T cells while reducing monocytic MDSCs, enhancing anticancer immune responses across cancers including melanoma.",{"@graph":69,"@context":123},[70,84,106],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/protac-mediated-nr4a1-degradation-as-a-novel-strategy-for-cancer-immunotherapy-article/340898/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/protac-mediated-nr4a1-degradation-as-a-novel-strategy-for-cancer-immunotherapy-article/340898.png","ImageObject",300,407,{"name":92,"@type":93},"Patrick","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-14","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":105},"InteractionCounter",{"@type":104},"ViewAction",11,{"@type":107,"mainEntity":108},"FAQPage",[109,115,119],{"name":110,"@type":111,"acceptedAnswer":112},"What is the main therapeutic goal described in the study?","Question",{"text":113,"@type":114},"To kill cancer cells and target the tumor microenvironment (TME) to enhance antitumor immunity.","Answer",{"name":116,"@type":111,"acceptedAnswer":117},"How is NR4A1 used in the proposed immunotherapy strategy?",{"text":118,"@type":114},"NR4A1 is identified as a molecule that maintains an immune-suppressive TME and is validated as a target for cancer immunotherapy.",{"name":120,"@type":111,"acceptedAnswer":121},"What is NR-V04 and what does it do?",{"text":122,"@type":114},"NR-V04 is a PROTAC designed against NR4A1, degrading NR4A1 within hours in vitro and producing long-lasting degradation in tumors.","https://schema.org",{"og:url":83,"og:type":125,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":127,"canonical":83},"index,follow",{"doc_id":129,"site_id":62},340898,1790499893,{"code":4,"msg":5,"data":132},{"doc_id":129,"user_id":133,"nickname":92,"user_avatar":134,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":105,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":140,"language":141,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":142,"faqs":143,"seo_title":144,"seo_description":67,"update_tm":145,"read_time":146,"preview_page_count":19,"preview_urls":147},549758146520,"https://ap-avatar.wpscdn.com/avatar/80002397d8c0411e94?_k=1775819394049821470","ARTICLE  \nPROTAC-mediated NR4A1 degradation as a novel strategy for cancer immunotherapy  \nLei Wang1*􀀁, Yufeng Xiao2*􀀁, Yuewan Luo1􀀁, Rohan P. Master1􀀁, Jiao Mo1􀀁, Myung-Chul Kim1,3􀀁, Yi Liu2􀀁, Chandra K. Maharjan1􀀁, Urvi M. Patel 1􀀁, Umasankar De1􀀁, Madison E. Carelock1􀀁, Tanzia Islam Tithi1􀀁, Xiangming Li4􀀁, Donald R. Shaffer4􀀁, Kevin R. Guertin5􀀁, Haoyang Zhuang6􀀁 , Emily Moser7􀀁, Keiran S. M. Smalley8􀀁, Dongwen Lv9􀀁, Daohong Zhou9􀀁, Guangrong Zheng2,10􀀁, and Weizhou Zhang1,10􀀁  \nAn effective cancer therapy requires killing cancer cells and targeting the tumor microenvironment (TME). Searching for molecules critical for multiple cell types in the TME, we identified NR4A1 as one such molecule that can maintain the immune suppressive TME. Here, we establish NR4A1 as a valid target for cancer immunotherapy and describe a first-of-its-kind proteolysis-targeting chimera (PROTAC, named NR-V04) against NR4A1. NR-V04 degrades NR4A1 within hours in vitro and exhibits long-lasting NR4A1 degradation in tumors with an excellent safety profile. NR-V04 inhibits and frequently eradicates established tumors. At the mechanistic level, NR-V04 induces the tumor-infiltrating (TI) B cells and effector memory CD8+ T (Tem) cells and reduces monocytic myeloid-derived suppressor cells (m-MDSC), all of which are known tobe clinically relevant immune cell populations in human melanomas. Overall, NR-V04–mediated NR4A1 degradation holds promise for enhancing anticancer immune responses and offers a new avenue for treating various types of cancers such as melanoma.  \nIntroduction  \nThe tumor microenvironment (TME) consists of many cell types that cooperatively promote tumor development and progression. Most cancer therapeutics are designed to target one molecule in one defined cell type. For example, vemurafenib (BRAF inhibitor) inhibits melanoma through targeting mutated BRAF, whereas pembrolizumab (anti–PD-1 antibody) blocks the immune checkpoint PD-1 on T cells to increase antitumor immunity. Several FDA-approved combination therapies involve cancer cell–killing chemotherapies and immune checkpoint inhibitors (ICI) to activate anticancer immunity within the TME, suggesting that cotargeting cancer cells and other cell types within the TME can be effective therapeutic regimens.  \nNR4A1 is an intracellular transcription factor that is known for its role in immune regulation and other functions (Fassettet al., 2012; Hiwa et al., 2021; Liu et al., 2019; Tan et al., 2020) . Within the TME, NR4A1 acts upon several cell types, as we recently summarized (Carelock et al., 2023): (1) NR4A1 is involved  \nin angiogenesis in the B16 melanoma model (Zeng et al., 2006) . The impact of NR4A1 on neoangiogenesis has also been confirmed in several other models (Chen et al., 2020; Ha et al., 2008; Ismail et al., 2012; Ye et al., 2019) . As neoangiogenesis in tumors induces the formation of new blood vessels with increased permeability, NR4A1 plays a critical role in regulating basal vascular permeability by increasing endothelial nitric-oxide synthase and downregulating several junction proteins involved in adherens junctions and tight junctions (Zhao et al., 2011) . (2) The NR4A family has been shown to be elevated in exhausted CD8+ T cells (Texh), and their deletion rescues the cytotoxicity function of CD8+ T cells (Chen et al., 2019a; Liu et al., 2019) . (3) Tumor-infiltrating (TI) regulatory T (Treg) cells rely on NR4A family members for their immune suppressive function (Fassett et al., 2012; Hibino et al., 2018) . (4) NR4A1 can be induced in TI natural killer (TI-NK) cells through the IFN-γ/ STAT1/IRF1 signaling pathway, which leads to diminished NK  \n............................................................................................................................... ..............................................  \n1Department of Pathology, Immunology and Laboratory Medicine, College of Medicine, University of Florida, Gainesville, FL, USA; 2Department of","cbCaihBHQ0SMoEIs","https://ap.wps.com/l/cbCaihBHQ0SMoEIs","pdf",7274809,22,"English","# Introduction\n## Tumor microenvironment targeting and rationale\n## NR4A1 roles across immune and stromal cell types\n## Rationale for PROTAC-mediated NR4A1 degradation","[{\"question\":\"What is the main therapeutic goal described in the study?\",\"answer\":\"To kill cancer cells and target the tumor microenvironment (TME) to enhance antitumor immunity.\"},{\"question\":\"How is NR4A1 used in the proposed immunotherapy strategy?\",\"answer\":\"NR4A1 is identified as a molecule that maintains an immune-suppressive TME and is validated as a target for cancer immunotherapy.\"},{\"question\":\"What is NR-V04 and what does it do?\",\"answer\":\"NR-V04 is a PROTAC designed against NR4A1, degrading NR4A1 within hours in vitro and producing long-lasting degradation in tumors.\"}]","PROTAC-mediated NR4A1 degradation as a novel strategy for cancer immunotherapy - Article | PDF",1790039461,55,[148,152,156,160],{"page_no":8,"url":149,"width":150,"height":151},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/8239610b22acc07f16b6de76b6c20563.webp",983,1272,{"page_no":14,"url":153,"width":154,"height":155},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/bb0c6f9f38c49da29b8ab04c020b0460.webp",982,1270,{"page_no":81,"url":157,"width":158,"height":159},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/503caadf71fd958329b57162948abcae.webp",981,1269,{"page_no":19,"url":161,"width":162,"height":163},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/a73bad62f6abc447020258294c6e27f6.webp",980,1268]